Posted on

Field Trip Adds Acclaimed Physician, Dr. Andrew Weil, to Medical Advisory Board

Global Leader in Holistic and Integrative Medicine to Assist Field Trip with Enhancing Treatments and Future Expansion Plans

TORONTO, Oct. 8, 2020 /PRNewswire/ — Field Trip Health Ltd. (CSE: FTRP) (“Field Trip”), the global leader in the development and delivery of technology-enabled psychedelic therapies, today announced the addition of Andrew Weil, M.D., world-renowned leader and pioneer in the field of integrative medicine, to its medical advisory board. In this role, Dr. Weil will provide Field Trip with medical advice and expertise on healing-oriented approaches to healthcare, as well as guidance on extending the influence and reach of psychedelic therapies.

Combining a Harvard education and a lifetime of practicing natural and preventive medicine, Dr. Weil is the founder and director of the Andrew Weil Center for Integrative Medicine at the University of Arizona, where he also holds the Lovell-Jones Endowed Chair in Integrative Rheumatology, and is Clinical Professor of Medicine and Professor of Public Health. The Center is leading the effort to develop a comprehensive curriculum in integrative medicine. Graduates serve as directors of integrative medicine programs throughout the United States, and through its fellowship, the Center is now training doctors and nurse practitioners around the world.  Dr. Weill is one of the most respected physicians in the world and has decades of personal and professional experience with the healing nature of psychedelics.

“I am extremely pleased to be joining the medical advisory board at Field Trip,” said Dr. Weil. “Field Trip’s mission, as well as the energy, enthusiasm and commitment to thoughtful, modern and responsible approaches to psychedelic medicine that the team at Field Trip is pursuing are remarkable. They are consistent with, not only my approach to the practice of medicine, but how I see modern approaches to medicine evolving. More and more, we are seeing that the mind plays an essential role in medicine and healing and Field Trip is at the forefront of revolutionizing mental, emotional and behavioural health through psychedelic therapies.”

“It is an honour and privilege to welcome Dr. Weil to our medical advisory board. Andy is widely recognized as one of the forefathers of modern integrative medicine. He is internationally recognized for his thought leadership in medicine, healthcare and the therapeutic applications of once-stigmatized drugs and medicines.  Andy’s experience working with psychedelics is unparalleled, and helped form the basis for his integrated medical philosophy. His unique insights will provide critical guidance as we grow our footprint in and cultivate our treatment framework from start to post-experience integration for the people seeking treatment in our centers,” said Ronan Levy, Field Trip’s Executive Chairman.

Field Trip recently announced the opening of its Field Trip Health centers in New York City, Los Angeles, and Toronto, which are providing best-in-class, technology-enabled psychedelic-assisted psychotherapy.

About Field Trip Health Ltd.

Field Trip is the global leader in the development and delivery of psychedelic therapies. With Field Trip Discovery leading the development of the next generation of psychedelic molecules and conducting advanced research on plant-based psychedelics, Field Trip Health hubs for psychedelic therapies opening across North America, and Field Trip Digital building the digital and technological tools to support psychedelic experiences and consciousness expansion, we help people, from those in treatment to those seeking accelerated personal growth, with a simple, evidence-based way to heal and heighten engagement with the world.

Learn more at https://www.meetfieldtrip.com and https://www.fieldtriphealth.com

Follow us on Twitter and Instagram: @fieldtriphealth

To receive company updates about Field Trip and to be added to the email distribution list please sign up here.

Cautionary Note Regarding Forward Looking Information

This release includes forward-looking information within the meaning of Canadian securities laws regarding Field Trip and its business, which may include, but are not limited to, statements with respect to the listing of the common shares of Field Trip on the Canadian Securities Exchange, and the timing of such events. Often but not always, forward-looking information can be identified by the use of words such as “expect”, “intends”, “anticipated”, “believes” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would” or “will” be taken, occur or be achieved. Such statements are based on the current expectations and views of future events of the management of Field Trip, and are based on assumptions and subject to risks and uncertainties. Although the management of Field Trip believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the companies, including risks regarding the COVID-19 epidemic, the medical clinic industry, market conditions, economic factors, management’s ability to manage and to operate the business and the equity markets generally. Although Field Trip has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Field Trip does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

The CSE has neither approved nor disapproved the contents of this news release.

 

CisionView original content:http://www.prnewswire.com/news-releases/field-trip-adds-acclaimed-physician-dr-andrew-weil-to-medical-advisory-board-301148564.html

SOURCE Field Trip Health Ltd.

Posted on

Core One Labs Signs Letter of Intent to Acquire Vocan Biotechnologies

Vancouver, British Columbia, Canada – October 7, 2020 – Core One Labs Inc. (CSE: COOL), (OTCQX: CLABD), (Frankfurt: LD62, WKN: A2P8K3) (the “Company”) is pleased to announce it has entered into a Letter of Intent (the “LOI”) dated effective October 1, 2020 to acquire all of the outstanding share capital of Vocan Biotechnologies Inc. (“Vocan”).

Vocan is a genetic engineering and biosynthesis research firm developing a proprietary fermentation system for the production of psilocybin API.  Vocan’s mission is to use science and technology to advance the knowledge of natural-based medicines for the treatment of mental health illnesses, including addictions. Vocan’s team of scientists, specializing in protein expression and biosynthetic fermentation, have discovered a patentable method of producing psilocybin, the active ingredient in psychotropic mushrooms, and its technology will produce cGMP API grade psilocybin, which can be used by pharmaceutical companies, API manufacturers and medical research organizations conducting clinical trials.  Vocan’s management expects that the unique optimized DNA construct and producer strain will allow for time efficient and cost-effective cGMP API grade psilocybin at commercial scale.  Psilocybin production methods developed by Vocan could provide more affordable access to organizations looking to acquire GMP API grade psilocybin. 

CEO and Founder of Vocan Biotechnologies

Dr. Robert E.W. Hancock, CEO and Chairman of Vocan, is a leading researcher at the University of British Columbia, a Killam Professor of Microbiology and Immunology, and a Canada Research Chair in Health and Genomics.  He is a co-founder of several companies, both private and public, including Migenix, Inimex, ABT Innovations and Sepset Biotherapeutics.  He has won major health research awards and is an Officer of the Order of Canada. Dr Hancock will continue as CEO of Vocan following completion of the acquisition.

Dr. Jan Burian, Founder and CTO of Vocan, is a successful biochemist and molecular biologist with extensive knowledge and an exclusive skill set in fermentative API-grade research, development and production. He has been cited in numerous academic publications.  Dr. Burian previously held a site directorship with Pfizer Canada where he was responsible for a vaccine manufacturing facility that relied on his advanced fermentation techniques.

Dr. Hancock and Dr. Burian first began collaborating over twenty years ago and together bring a unique combination of broad scientific know-how and skill as they get set to take Vocan’s exclusive psilocybin production capabilities to commercial scale.

“We are honored and privileged to work with scientists of Dr. Hancock’s and Dr Burian’s caliber”, Joel Shacker, Chief Executive Officer of the Company stated. “Combined with the Company’s existing infrastructure, and the integration of its intellectual property related to psychedelic treatments and novel drug therapies, an acquisition of Vocan, and its talented research team, only furthers the Company development in the alternative psychedelics medicine market.”

Terms of the LOI

Under the terms of the LOI, in consideration for all of the outstanding share capital of Vocan, the Company is expected to issue 23,500,000 common shares (the “Consideration Shares”), and 4,000,000 common share purchase warrants (the “Consideration Warrants”), to the existing shareholders of Vocan.  Each Consideration Warrant will be exercisable to acquire an additional common share of the Company at a price of $0.30 for a period of twenty-four months.

In addition to the Consideration Shares, and the Consideration Warrants, the existing shareholders of Vocan will also be eligible to receive bonus payments of up to 5,000,000 common shares (the “Bonus Shares”).  The Bonus Shares will be issuable in two tranches, of which 2,500,000 will be issuable upon the successful synthesis of psilocybin, and a further 2,500,000 will be issuable upon the filing of a patent application for such synthesis method in at least one jurisdiction.

It is anticipated that a portion of the Consideration Shares will be subject to the terms of a pooling arrangement, during which time they not be transferred or traded without the prior consent of the Company.  The Consideration Shares will be released from the arrangement in tranches over a period of nine months following completion of the acquisition.

Completion of the acquisition of Vocan remains subject to a number of conditions, including the satisfactory completion of due diligence, receipt of any required regulatory approvals and the negotiation of definitive documentation.  The acquisition cannot be completed until these conditions have been satisfied.

The Company is at arms-length from Vocan, and each of its shareholders.  The acquisition of Vocan is not expected to constitute a fundamental change for the Company, nor is it expected to result in a change of control of the Company, within the meaning of applicable securities laws and the policies of the Canadian Securities Exchange.  No finders fees or commissions are payable in connection with the acquisition of Vocan.  An administrative fee of 470,000 common shares is owing to a third-party consultant who will be assisting with completion of the acquisition.

About Core One Labs Inc.

Core One Labs Inc. is a research and technology company with a state-of-the-art cannabis production and packaging facility located in Southern California. The Company’s technology produces infused strips (like breath strips) that are not only a safer, healthier option to other forms of delivery but also superior bioavailability of cannabis constituents. The technology provides a new way to accurately meter the dosage and assure the purity of selected product.  The Company holds an interest in walk-in medical clinics located in Vancouver and West Vancouver, British Columbia which maintain a database of over 200,000 patients combined.  The Company intends to further develop its product offerings through research and development in these clinics, including the integration of intellectual property related to psychedelic treatments and novel drug therapies.

Core One Labs Inc.

Joel Shacker

Chief Executive Officer

FOR MORE INFORMATION, PLEASE CONTACT:

info@core1labs.com

1-866-347-5058

Cautionary Disclaimer Statement:

The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management’s current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. The Company cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond the Company’s control. Such factors include, among other things: risks and uncertainties relating to the Company’s limited operating history and the need to comply with environmental and governmental regulations. In addition, marijuana remains a Schedule I drug under the United States Controlled Substances Act of 1970.  Although Congress has prohibited the US Justice Department from spending federal funds to interfere with the implementation of state medical marijuana laws, this prohibition must be renewed each year to remain in effect.  Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.

Posted on

TRYP THERAPEUTICS ANNOUNCES FORMATION OF PSILOCYBIN SCIENTIFIC ADVISORY BOARD

Drs. Rachel Wevrick and Derek Ott to advise on drug development programs

La Jolla, California, Oct 06, 2020 (Newsfile Corp via COMTEX) — La Jolla, California–(Newsfile Corp. – October 6, 2020) – Tryp Therapeutics Inc. (“Tryp” or the “Company“), a pharmaceutical company developing therapeutics specifically targeting diseases with high unmet medical needs announced today the formation of a Scientific Advisory Board (“SAB“) for its Psilocybin For Neuropsychiatry (“PFN™“) program. The PFN™ SAB is a preeminent group of experts in neuropsychiatry research and clinical care specifically chosen to advise on the Company’s TRP-8802, TRP-8803 and TRP-8804 investigational drugs.

Tryp has entered into consulting agreements with Dr. Rachel Wevrick, PhD, of University of Alberta, and Dr. Derek Ott, MD, MS, of University of California, Los Angeles (UCLA) School of Medicine. Dr. Wevrick is Professor, Department of Medical Genetics, at University of Alberta. Her research is focused on the genetic, molecular, and physiological basis of abnormal neurodevelopment, growth and metabolism in developmental disorders affecting children. Her specific areas of interest include: Prader-Willi syndrome (“PWS“) and Translational research in PWS, Schaaf-Yang syndrome, and other neurodevelopmental disabilities that are caused by de novo or inherited genetic mutations that affect the function of the brain and nervous system including Bardet-Biedl syndrome, Tourette syndrome, and severe early onset obesity with intellectual disability. She earned her PhD from the Department of Molecular and Medical Genetics, University of Toronto and completed post-doctoral fellowships in the Department of Genetics at The Hospital for Sick Children Research Institute, and at Howard Hughes Medical Institute, Stanford University School of Medicine.

Dr. Derek Ott is associate clinical professor of psychiatry at UCLA School of Medicine, the director of the UCLA Pediatric Neuropsychiatry Clinic and a psychiatric consultant for Westside and Frank D Lanterman Regional Centers in Los Angeles. He is board certified physician in in both child and adolescent as well as adult psychiatry. Dr. Ott graduated from Stanford University with honors and a degree in human biology. He then attended the University of Illinois in Urbana-Champaign, where he completed his medical and graduate training (Masters in Neuroscience). Dr. Ott began his clinical training in psychiatry at the University of California-Los Angeles Resnick Neuropsychiatric Hospital in Westwood, where he completed a residency in Adult Psychiatry , as well as a fellowship in Child and Adolescent Psychiatry. Following this clinical training, Dr. Ott participated in a NIMH sponsored post-doctoral fellowship which focused on psychopathology in pediatric epilepsy. Dr. Ott has particular expertise in the areas of neuropsychiatry, developmental disabilities, attention-deficit hyperactivity disorder and childhood psychosis. He has extensive experience working with individuals with neurological disorders, developmental disabilities (i.e. autism and intellectual disability), as well as comorbid behavioral/psychiatric disorder. His private practice focuses on psychopharmacology in children, adolescents, and adults.

“Working with Drs. Wevrick and Ott fulfill a critical component of our development strategy focused on accelerating psilocybin clinical testing. We are very pleased to have two such well recognized key opinion leaders support our PFN™ program. By working with them, we are able to design the optimal drug development pathway for fibromyalgia and Prader-Willi Syndrome,” said Tom D’Orazio, Chief Operating Officer of Tryp.

About Tryp Therapeutics:

Tryp Therapeuticsis an early stage pharmaceutical development company led by a management team with extensive drug development experience that is advancing transformative medicines with existing clinical data and known safety profiles for diseases with no effective first-line treatments. The Company is building a diversified portfolio of product candidates targeting neuropsychiatric and oncology indications with high unmet medical needs.

Contact:
TRYP Therapeutics Inc.
James Kuo, MD, MBA, Chief Executive Officer
E: jkuo@trytherapeutics.com
T: 1-833-811-TRYP (8797)

Forward Looking Statements

Certain statements in this press release may constitute forward-looking information. All statements other than statements of historical fact contained in this press release, including, without limitation, those regarding Tryp’s future, strategy, plans, objectives, goals and targets, and any statements preceded by, followed by or that include the words “believe”, “expect”, “aim”, “intend”, “plan”, “continue”, “will”, “may”, “would”, “anticipate”, “estimate”, “forecast”, “predict”, “project”, “seek”, “should” or similar expressions or the negative thereof, are forward-looking statements. These statements are not historical facts but instead represent only Tryp’s expectations, estimates and projections regarding future events. These statements are not guaranteeing future performance and involve assumptions, risks and uncertainties that are difficult to predict. Therefore, actual results may differ materially from what is expressed, implied or forecasted in such forward-looking statements. The forward-looking information and forward-looking statements included in this press release are made as of the date of this press release. The Company does not undertake an obligation to update such forward-looking information or forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities law.

Posted on

Minnesotans Petition State to Include Anxiety, Sickle Cell Disease, and Tic Disorder as Qualifying Conditions for Medical Cannabis

A coalition of patients, advocates and physicians are petitioning the Minnesota Department of Health to add new qualifying conditions for medical cannabis

MINNEAPOLIS, Oct. 6, 2020 /PRNewswire/ — Vireo Health of Minnesota, LLC (“Vireo” or “the Company”), a subsidiary of Vireo Health International, Inc. (CNSX: VREO, OTCQX: VREOF), today announced that the Company is joining a growing coalition of patients, advocates, and physicians to petition the Minnesota Department of Health (“MDH”) to expand the state’s Medical Cannabis Program. The MDH is currently accepting public written comment on the addition of three new qualifying medical conditions – anxiety, sickle cell disease, and tic disorder.

Vireo Logo (PRNewsfoto/Vireo Health, Inc.)

Vireo is helping Minnesotans to take action through a digital advocacy campaign that allows people to pledge their support for adding anxiety, sickle cell disease, and tic disorder as qualifying conditions for medical cannabis use. Adding these conditions will allow certified physicians to prescribe medical cannabis to patients who are diagnosed with any of these ailments.

“Our goal is to make medical cannabis accessible for those in Minnesota who suffer from anxiety, sickle cell disease, and tic disorder,” said Vireo’s Chief Medical Officer Stephen Dahmer, M.D. “Now more than ever, adjunct therapies are needed to address the issues and challenges arising from the COVID-19 pandemic – such as anxiety. It is equally important to include conditions, such as Sickle Cell Disease, which disproportionately impact communities of color. We ask the MDH to review the available research and data which supports the benefit of offering Minnesotans impacted by these conditions access to medical cannabis in the safety of a closely monitored program.”

Support for Each Proposed Qualifying Condition

Anxiety – Research has shown that medical cannabis can reduce anxiety in patients being treated for other qualifying conditions, such as chronic pain and cancer. A majority of older patients when surveyed report cannabis to be extremely or somewhat helpful for anxiety and additional research supports the reduction of benzodiazepine use in medical cannabis patients.

Sickle Cell Disease – Recent research supports the ability of medical cannabis to not only reduce pain associated with Sickle Cell Disease, but also to be a cost-effective alternative that could reduce hospital admissions.

Tic Disease – Both research and Vireo’s own anecdotal evidence of treating Minnesota patients with the State-approved qualifying condition, Tourette Syndrome, support the ability of cannabis to safely decrease the intensity of tics, as well as slow the tic urge, among other positive benefits.

“These three conditions merit consideration from the Minnesota Department of Health. We remain hopeful that Minnesota will expand its list of qualifying conditions,” said Dr. Sujit Varma, MD, a Minneapolis-based physician certified by the American Board of Psychiatry and Neurology. “Research has shown that medical cannabis can provide ample relief and serves as a safer alternative to traditional pharmaceuticals.”

For patients and advocates who want to get involved, please visit the Vireo Health of Minnesota website advocacy page and act now!

About Vireo Health of Minnesota
Vireo Health of Minnesota, LLC is one of two licensed medical cannabis companies in Minnesota. Vireo operates four Cannabis Patient Centers across the state and a cultivation and processing facility near Otsego, MN. Vireo Health of Minnesota is a subsidiary of Vireo Health International, Inc. Vireo’s mission is to build the cannabis company of the future by bringing the best of medicine, engineering, and science to the cannabis industry. Vireo’s physician-led team of more than 400 employees provides best-in-class cannabis products and patient experience. For more information about Vireo, please visit www.vireohealth.com.

Contact Information 
Albe Zakes
albezakes@vireohealth.com
(267) 221-4800

 

CisionView original content to download multimedia:http://www.prnewswire.com/news-releases/minnesotans-petition-state-to-include-anxiety-sickle-cell-disease-and-tic-disorder-as-qualifying-conditions-for-medical-cannabis-301146643.html

SOURCE Vireo Health International, Inc.

Posted on

HAVN LIFE SCIENCES ANNOUNCES APPOINTMENTS OF VIC NEUFELD AS CHAIRMAN AND RICK BRAR AS VICE CHAIRMAN OF THE BOARD OF DIRECTORS, RESPECTIVELY, AND THE ACCELERATION OF WARRANTS

Vancouver, BC – Havn Life Sciences Inc. (CSE : HAVN) (FSE : 5NP)(the “Company” or “Havn Life”), is pleased to announce that Mr. Vic Neufeld has been appointed as the Chairman of the Board of Directors of the Company (the “Board”). Mr. Neufeld brings a wealth of knowledge and experience in the Natural Health Food industry, having served as the Chief Executive Officer of Jamieson Laboratories (“Jamieson”), Canada’s largest manufacturer and distributor of natural vitamins, minerals, concentrated food supplements, herbs and botanical medicines. During Mr. Neufeld’s 21-year tenure with Jamieson the company went from $20 million in annual sales to over an estimated $250 million and expanded its distribution network to over 40 countries, building Jamieson to a globally recognized brand name. Mr. Neufeld is also the former President and Chief Executive Officer of Aphria Inc., a medical marijuana and cannabis oil company. Mr. Neufeld’s educational background includes a Bachelor of Economics from Western University, an Honours degree in Business from the University of Windsor and a Master of Business Administration from the University of Windsor. Mr. Neufeld is also a chartered professional accountant.

Mr. Neufeld stated, “It is clear to me that the psychedelics sector is very real and could be a catalyst of disruptive change to the health and wellness market. I believe Havn Life is uniquely positioned with the right operational team, vision and business model to establish itself as a leader in this sector, both in terms of the work it’s doing to create a leading nutraceutical wellness brand via the Havn Retail division, and in carrying out cutting-edge research and development through the Havn Labs division.”

The Company further announces that Mr. Rick Brar has been appointed as the Vice Chairman of the Board. Mr. Brar is an experienced business leader in the cannabis, nutraceutical, beverage, consumer packaged goods, agriculture, land development and construction sectors. Mr. Brar has international expertise in emerging market sectors, having incubated and grown several companies over his career. He is experienced in sales and marketing, with a track record of success in corporate sales growth, new market penetration, new product development, and long-range planning. Mr. Brar is also experienced in team building, strategic planning, new market development and the implementation of tactical sales and marketing initiatives. Mr. Brar was previously the Chief Executive Officer of Atlas Supply Company Limited, where he led one of the largest herb companies in North America for nine years. Mr. Brar was also previously the Chief Executive Officer of Zenabis Global Inc., a leading Canadian cultivator of medical and adult-use recreational cannabis and a propagator and cultivator of floral and vegetable products. Mr. Brar is currently the Chief Executive Officer & Chairman of Brains Bioceutical Corp. a global manufacturer and distributor of Cannabinoid API.

Furthermore, the Company announces the acceleration of outstanding warrants (“Accelerated Warrants”) that were issued in connection with a previous non-brokered private placement of units by the Company. Each Accelerated Warrant entitles the holder thereof to purchase one Common Share at a price of $0.50; the original exercise period of the Accelerated Warrants was 24 months, however, as a result of the Common Shares trading above $0.75 for the last 10 trading days, the exercise period has been accelerated such that it now expires within 30 days.  The Company has been notified by Mr. Neufeld that he will be participating in the warrant exercise.

The Company also announces the departure of Robert Nygren as Co-head of Corporate Development and as a director of the Company, effective immediately. The Company expresses its appreciation for Robert’s services to the Company, particularly in relation to his involvement with ETC3 Holdings Ltd., a co-founder of the Company, and wishes him well in his future endeavourst.

On Behalf of The Board of Directors
Susan Chapelle & Tim Moore
Co-CEOs

About Havn Life Sciences Inc.

Havn Life Sciences is a biotechnology company on a mission to unlock human potential using evidence-informed research. The Company is focused on standardized, quality-controlled extraction of psychoactive compounds from plants and fungi, and the development of natural health care products from non-regulated compounds. Learn more at: havnlife.com and follow us on Facebook, Twitter and Instagram.

Connect

Investor Relations
ir@havnlife.com
604 (687)-7130

Facebook: @havnlife
Twitter: @havnlife
Insta: @havn.life
LinkedIn: @Havn Life

Media Contact
Brittany@exvera.com
778-238-6096

 

Li
Posted on

Vireo Health Provides Corporate Governance Update

VIEW ALL NEWS

Posted on

DR. ROGER MCINTYRE ELECTED BOARD CHAIR OF CHAMPIGNON BRANDS INC.

VANCOUVER, BRITISH COLUMBIA (October 5, 2020) – Dr. Roger McIntyre has been elected Chairman of the Board of Directors of Champignon Brands Inc. (“Champignon” or the “Company”) (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF).

A foremost international expert in depression and suicide, Dr. McIntyre is a Professor of Psychiatry and Pharmacology at the University of Toronto, heads the Mood Disorders Unit at the University Health Network in Toronto and has appointments among scientific and clinical organizations across the US and Asia.

Dr. McIntyre was appointed to the Board of Directors of Champignon on July 22, 2020 and assumed the role of CEO on May 11, 2020.  He has set out a strategic direction for the business which includes a focus on “breakthrough treatments of depression” through the development of government-approved ketamine compounds and a network of treatment clinics. The Company’s dual mission is to help those suffering from mental health disorders in its own ketamine-based clinics and to develop the next generation of novel psychedelic treatments and delivery systems.

The Company continues to work with the British Columbia Securities Commission to address the ongoing continuous disclosure review and is confident that the review will be resolved soon.

Bill Wilkerson, LL. D. (Hon), appointed to the Board of Directors of Champignon on May 22, 2020, has been elected Vice-Chair of the Board, bringing to the position extensive experience in business, government, and mental health.

For more information on Champignon Brands Inc. please visit our website:  https://braxiascientific.com.

Investor inquiries: +1 (833) 375-9995 x611 or champignonbrands@storyboardcommunications.com

Information: info@braxiascientific.com

The Canadian Securities Exchange and its Information Service Provider have not reviewed and do not accept responsibility for the accuracy or adequacy of this release.

Forward-looking Information Cautionary Statement

This news release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations, or beliefs of future performance are “forward-looking statements.” Forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events, or developments to be materially different from any future results, events or developments expressed or implied by such forward looking statements.  These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements. Although the Company has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company’s filings with Canadian securities regulators, which are available at www.sedar.com.  There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. The Company has no obligation to update any forward-looking statement, even if new information becomes available.

Posted on

MindMed Partners with NYU Langone Medical Center to Launch Groundbreaking Training Program for Psychedelic Therapies and Medicines

NEW YORK, Oct. 5, 2020 /PRNewswire/ — MindMed (NEO: MMED) (OTCQB: MMEDF), the leading psychedelic medicine biotech company, on the heels of filing a NASDAQ uplisting application, today announced a funding commitment to found and launch a clinical training program focused on psychedelic assisted therapies and psychedelic inspired medicines at NYU Langone Health, one of the nation’s premier academic medical centers. The NYU Langone Health Psychedelic Medicine Research Training Program is the first step in a larger initiative to establish a Center for Psychedelic Medicine at NYU Langone Health.

“NYU Langone Health and the NYU Grossman School of Medicine are ideal partners for MindMed as we continue to evaluate and research future psychedelic assisted therapies and medicines for substance abuse disorders and other mental illnesses,” said MindMed Co-Founders and Co-Chief Executive Officers J.R. Rahn and Stephen L. Hurst. “In order for our industry and company to turn these once stigmatized substances into medicines, we need to build the critical training infrastructure in the United States to train clinical researchers, psychiatrists, mental health professionals and substance abuse counselors who will ultimately be our close partners in delivering these future potential therapies and medicines to millions of patients in need.”

‍

MindMed is committing $5 million over a five-year period to the NYU Langone Health Psychedelic Medicine Research Training Program and the future corresponding Center for Psychedelic Medicine at NYU Langone Health. NYU Langone Health will have full and free discretion in using these funds for the development and conduct of the training program and operations of the Center for Psychedelic Medicine. The launch of the Center for Psychedelic Medicine at NYU Langone Health is still subject to additional funding from other undisclosed partners and parties.

‍

Link to article here: https://www.prnewswire.com/news-releases/mindmed-partners-with-nyu-langone-medical-center-to-launch-groundbreaking-training-program-for-psychedelic-therapies-and-medicines-301145393.html

‍

About MindMed
MindMed is a psychedelic medicine biotech company that discovers, develops and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT and an Ibogaine derivative, 18-MC. The MindMed executive team brings extensive biopharmaceutical experience to the company’s groundbreaking approach to developing the next-generation of psychedelic inspired medicines and therapies.

MindMed trades on the Canadian exchange NEO under the symbol MMED. MindMed is also traded in the United States under the symbol MMEDF and in Germany under the symbol MMQ. For more information: www.mindmed.co

MindMed Forward-Looking Statements
This press release includes forward-looking statements that involve risks and uncertainties relating to future events and performance of Mind Medicine (MindMed) Inc. (“MindMed”), and actual events or results may differ materially from these forward-looking statements. Words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, MindMed’s and its collaborators’ ability to continue to conduct research and clinical programs, MindMed’s ability to manage its supply chain, product sales of products marketed by MindMed and/or its collaborators (collectively, ” Products”), and the global economy; the nature, timing, and possible success and therapeutic applications of Products and Product candidates and research and clinical programs now underway or planned; the likelihood, timing, and scope of possible regulatory approval and commercial launch of Product candidates and new indications for Products; unforeseen safety issues resulting from the administration of Products and Product candidates in patients, including serious complications or side effects in connection with the use of MindMed’s Products and product candidates in clinical trials; determinations by regulatory and administrative governmental authorities which may delay or restrict MindMed’s ability to continue to develop or commercialize Products; ongoing regulatory obligations and oversight impacting Products, research and clinical programs, and business, including those relating to patient privacy; uncertainty of market acceptance and commercial success of Products and Product candidates and the impact of studies on the commercial success of Products and Product candidates; the availability and extent of reimbursement of Products from third-party payers, including private payer healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; competing drugs and product candidates that may be superior to Products and Product candidates; the extent to which the results from the research and development programs conducted by MindMed or its collaborators may be replicated in other studies and lead to therapeutic applications; the ability of MindMed to manufacture and manage supply chains for multiple products and product candidates; the ability of MindMed’s collaborators, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labelling, distribution, and other steps related to MindMed’s Products and product candidates; unanticipated expenses; the costs of developing, producing, and selling products; the ability of MindMed to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license or collaboration agreement to be cancelled or terminated without any further product success; and risks associated with intellectual property of other parties and pending or future litigation relating thereto, other litigation and other proceedings and government investigations relating to MindMed and its operations, the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on MindMed’s business, prospects, operating results, and financial condition. Any forward-looking statements are made based on management’s current beliefs and judgment. MindMed does not undertake any obligation to update publicly any forward-looking statement.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities of the Company will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act, and may not be offered or sold within the United States or to, or for the account or benefit of U.S. persons except in certain transactions exempt from the registration requirements of the U.S. Securities Act)

Posted on

Wuhan General Group Appoints Willem Jonker as Chief Operating Officer

CAPE TOWN, SA / ACCESSWIRE / October 5, 2020 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) (“Wuhan” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is delighted to share today the appointment of Mr. Willem Jonker, CA(SA), as Chief Operating Officer of the Cannabis Cultivation Project effective immediately.

Willem is an experienced leader and a recognized international authority in the cannabis industry. He is most often referred to as the grandfather of medicinal cannabis in Africa.

Willem is a chartered accountant and formerly a senior partner at Allan Gray, the largest independent investment manager in South Africa. In 1999, he started and/or expanded four small asset management businesses throughout Southern Africa. In the process, he moved into the field of private equity, with a focus on telecommunications (telecoms licenses in the Democratic Republic of Congo, South Africa and Tanzania), energy (hydrogen, solar, “green” cement substitute, and low-energy lights), real estate (two large shopping centers among others), commodity trading and project finance (development finance institutions and equity and debt finance).

Since 2015, Willem has been building Medigrow Africa into the largest portfolio of licensed medicinal cannabis companies in Africa. Medigrow Africa’s mission is to give as many people as possible access to cannabis as a medicine.

“We are very pleased to welcome Mr. Willem Jonker to the Wuhan team,” commented Jeff Robinson, Chairman & CEO of Wuhan, “As COO, he will oversee all aspects of the Company’s cannabis business operations. His strong track record in operational management and financial engineering will make for a great addition to our executive team.”

“His ability to align project requirements and capital has been key in mounting such an impressive portfolio for Medigrow. Willem will leverage this strength across our Tsime project and other potential future acquisitions.”

“For me it is a great opportunity to bring Wuhan’s vision to life in a leadership role as COO,” said Willem. “My focus will be to support and implement Jeff’s strategic vision of developing and strengthening the Wuhan position and reputation as the plant-based cannabinoids biotech leader for the next decade.”

About Wuhan General Group, Inc./ M2Bio Sciences, Inc

Wuhan General Group, Inc. through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company that researches, develops and commercializes a range of CBD-based products under Dr. AnnaRx™ and Medspresso™ brands. In addition, its wholly-owned division, M2Bio is researching and developing indications for psilocybin new therapies that will help patients who suffer from addiction, mental illness, Alzheimer’s and Parkinson’s. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research and emerging technologies. Wuhan is listed and traded on the Over the Counter Bulletin Board of NASDAQ under the trading symbol “WUHN”.

For further information:

Publicly traded company (OTC Pink:WUHN)
Website: www.m2bio.co
E-mail:info@m2bio.co
Follow us on Twitter: https://twitter.com/m2bio
Follow us on Facebook: http://www.facebook.com/m2bio

Forward-Looking Statements:

Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences to include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.

SOURCE: Wuhan General Group, Inc.

View source version on accesswire.com:
https://www.accesswire.com/609109/Wuhan-General-Group-Appoints-Willem-Jonker-as-Chief-Operating-Officer

Posted on

Field Trip Health Ltd. to Commence Trading on the CSE on October 6 Under Ticker Symbol FTRP

Company launches new investor website at https://www.meetfieldtrip.com  

TORONTO, Oct. 5, 2020 /CNW/ — Field Trip Health Ltd. (formerly Newton Energy Corporation) (“Field Trip” or the “Company“) (CSE: FTRP), the global leader in the development and delivery of technology-enabled psychedelic therapies, is pleased to announce that its common shares will commence trading on the Canadian Securities Exchange (the “CSE”) under the symbol FTRP tomorrow, October 6, 2020.

To coincide with the public listing, Field Trip has launched a new site, https://www.meetfieldtrip.com, which provides interested investors with further information about its business strategy, including relevant financial data and the latest news and SEDAR filings. It also provides details of Field Trip’s integrated platform which combines psychedelic-enhanced psychotherapy, technology-enabled clinical hubs and telehealth remote care, and drug and product development. Using this integrative approach, Field Trip is developing patient-centric and evidence-based psychedelic approaches to behavioral and mental health.

Joseph del Moral, CEO of Field Trip, commented, “Our public listing will increase our visibility among investors as we continue our work to transform attitudes and approaches to mental, emotional and behavioural health through psychedelics. Transparency and open communication with our shareholders will remain a top priority going forward. I would encourage those investors who are interested in following our progress to explore the new website in more detail.”

To receive company updates and be added to the email distribution list please sign up here.

About Field Trip Health Ltd.

Field Trip is the global leader in the development and delivery of psychedelic therapies. With Field Trip Discovery leading the development of the next generation of psychedelic molecules and conducting advanced research on plant-based psychedelics, Field Trip Health hubs for psychedelic therapies opening across North America, and Field Trip Digital building the digital and technological tools to support psychedelic experiences and consciousness expansion, we help people, from those in treatment to those seeking accelerated personal growth, with a simple, evidence-based way to heal and heighten engagement with the world.

Learn more at https://www.meetfieldtrip.com and https://www.fieldtriphealth.com

Follow us on Twitter and Instagram:  @fieldtriphealth

Cautionary Note Regarding Forward Looking Information

This release includes forward-looking information within the meaning of Canadian securities laws regarding the Company and its business, which may include, but are not limited to, statements with respect to the listing of the common shares of the Company on the Canadian Securities Exchange, and the timing of such events. Often but not always, forward-looking information can be identified by the use of words such as “expect”, “intends”, “anticipated”, “believes” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would” or “will” be taken, occur or be achieved. Such statements are based on the current expectations and views of future events of the management of the Company, and are based on assumptions and subject to risks and uncertainties. Although the management of the Company believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the companies, including risks regarding the COVID-19 epidemic, the medical clinic industry, market conditions, economic factors, management’s ability to manage and to operate the business and the equity markets generally. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

The CSE has neither approved nor disapproved the contents of this news release.

This press release does not constitute an offer to sell or the solicitation of an offer to buy, and shall not constitute an offer, solicitation or sale in any state, province, territory or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state, province, territory or jurisdiction.  

CisionView original content:http://www.prnewswire.com/news-releases/field-trip-health-ltd-to-commence-trading-on-the-cse-on-october-6-under-ticker-symbol-ftrp-301145891.html

SOURCE Field Trip Health Ltd.